IMMUCELL CORP DE
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
ICCC$10.26+0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
Our financial statements, together with the notes thereto and the reports of the independent registered public accounting firms thereon, are set forth on Pages F-1 through F-25 at the end of this Annual Report. The index to these financial statements is as follows:
| Report of Wipfli LLP, Independent Registered Public Accounting Firm (PCAOB ID#344) | F-1 |
|---|---|
| Balance Sheets as of December 31, 2023 and 2022 | F-2 |
| Statements of Operations during the years ended December 31, 2023 and 2022 | F-3 |
| Statements of Stockholders’ Equity during the years ended December 31, 2022 and 2023 | F-4 |
| Statements of Cash Flows during the years ended December 31, 2023 and 2022 | F-5 to F-6 |
| Notes to Audited Financial Statements | F-7 to F-25 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.